Recombinant human growth hormone for injection

The drug Jintropin is a genetic engineering somatotropic hormone. Stimulates skeletal and somatic growth, and also has a pronounced effect on metabolic processes. Stimulates the growth of the bones of the skeleton, affecting the plate epiphysis tubular bones, bone metabolism. Promotes the normalization of body structure by increasing muscle mass and reducing body fat. In patients with growth hormone deficiency and osteoporosis, substitution therapy results in normalization of mineral composition and bone density. Increases the number and size of cells of muscles, liver, thymus gland, gonads, adrenals, thyroid gland. Stimulates the transport of amino acids into the cell and the synthesis of proteins, reduces the level of cholesterol, affecting the profile of lipids and lipoproteins. Suppress the release of insulin. Promotes the retention of sodium, potassium and phosphorus. Increases body weight, muscle activity and physical endurance.

Absorption of somatropin after subcutaneous administration is 80%, the maximum concentration in the blood plasma is achieved in 3-6 hours. Penetrates into well-perfused organs. Metabolized in the kidney and liver. The volume of distribution of somatropin is 0.49-2.11 l / kg. It is excreted by the kidneys and with bile (including 0.1% unchanged). The half-life after subcutaneous administration is 3-5 hours.